Phase II Study of Interleukin-2 for Alzheimer's Disease
This study is looking into whether a low dose of Interleukin-2 (Aldesleukin) can be a safe and helpful treatment for Alzheimer's disease. Researchers believe that in Alzheimer's, certain immune cells called regulatory T cells (Tregs) don't work as well, which can lead to inflammation in the brain. Interleukin-2 aims to boost these Tregs to reduce inflammation. We are looking for 40 participants, aged 50 to 86, who have been diagnosed with probable Alzheimer's disease. The main goal is to see if Interleukin-2 is safe and well-tolerated over a 6-month treatment period.
- Study design
- This is a Phase II, randomized, double-blind, placebo-controlled study involving 40 participants. This means some participants will receive Interleukin-2 and others a placebo (an inactive substance), without you or your doctors knowing which you receive.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The safety and tolerability of the treatment will be assessed at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase II Clinical Trial of Interleukin-2 in AD
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To assess the safety and the tolerability of IL-2 in AD patients6 months treatment phase
Primary endpoint: \- Number of participants with adverse events and with abnormal laboratory findings (serum chemistry, hematology)